Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers

Abstract

Gastric and esophageal cancers are as main cancers of the gastrointestinal (GI) tract, which are associated with poor diagnosis and survival. Several efforts were made in the past few decades to finding effective therapeutic approaches, but these approaches had several problems. Finding new biomarkers is a critical step in finding new approaches for the treatment of these cancers. Finding new biomarkers that cover various aspects of the diseases could provide a choice of suitable therapies and better monitoring of patients with these cancers. Among several biomarkers tissue specific and circulating microRNAs (miRNAs) have emerged as powerful candidates in the diagnosis of gastric and esophageal cancers. MiRNAs are small noncoding single-stranded RNA molecules that are found in the blood and regulate gene expression. These have numerous characteristics that make them suitable for being used as ideal biomarkers in cancer diagnosis. Research has indicated that the level and profile of miRNA in serum and plasma are very high. They are potentially noninvasive and sensitive enough to detect tumors in their primary stages of infection. Multiple lines of evidence indicate that the presence, absence, or deregulation of several circulating miRNAs (i.e., let-7a, miR-21, miR-93, miR-192a, miR-18a, and miR-10b for gastric cancer, and miR-21, miR-375, miR-25-3p, miR-151a-3p, and miR-100-3p for esophageal cancer) are associated with initiation and progression of gastric and esophageal cancers. The aim of this review is to highlight the recent advances in the roles of miRNAs in diagnosis and treatment of gastric and esophageal cancers.

MicroRNA in leukemia: Tumor suppressors and oncogenes with prognostic potential

“…Numerous miRNAs advance tumorigenesis and cancer progression by improving tumor development, angiogenesis, invasion, and immune evasion, while others have tumor suppressive effects (Gholamin et al, ; H. Mirzaei et al, ; Moridikia, Mirzaei, Sahebkar, & Salimian, ; Yeh, Moles, & Nicot, ). Hence, these molecules could be used as diagnostic, prognostic, and therapeutic biomarkers in various diseases such as cancer (Fathullahzadeh et al, ; Gholamin et al, ; Huan et al, ; Jafari et al, ; Jamali et al, ; Keshavarzi, Darijani, et al, ; Keshavarzi, Sorayayi, et al, ; Khanmohammadi, Mir, Baniebrahimi, & Mirzaei, ; Mashreghi et al, ; H. R. Mirzaei et al, ; H. Mirzaei, Sahebkar, Jaafari, Goodarzi, & Mirzaei, ; Saadatpour et al, ; Simonian, Mosallayi, & Mirzaei, ; Tavakolizadeh et al, ).…”

MicroRNAs and exosomes: key players in HIV pathogenesis

“…miRNAs, 18–25 nucleotides in length, are noncoding RNAs that are able to target mRNAs and regulate their expression . In terms of functionality, miRNAs are important agents for gene silencing and post‐transcriptional regulation of proteins.…”

Cancer stem cells as therapeutic targets of pancreatic cancer

“…Dysregulation of miRNAs is associated with initiation and progression of a wide range of diseases such as diabetes, cardiovascular diseases, cancer, neurodegenerative diseases, infection diseases, and depression . Hence, it seems that these molecules could be introduced as diagnostic, prognostic, and therapeutic biomarkers in different diseases . In this regard, several studies revealed that different miRNAs were related to pancreatic CSCs progression and could be employed as new targets in PC treatment .…”